Market research
ABBOTINDIA.NSE Abbott India Limited
NSE INR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 536B
- P/E ratio
- 33.2
- Analyst target
- 32467.375
- Dividend yield
- 0.0%
- Beta
- 0.06
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE358A01014
- Market cap
- 536B
- P/E ratio
- 33.2
- Analyst target
- 32467.375
- Dividend yield
- 0.0%
- Beta
- 0.06
About
About Abbott India Limited
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, hypothyroidism, central nervous system, vaccines, and multispecialty, including insomnia, vertigo, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.
Research context
Abbott India Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ABBOTINDIA.NSE discussion.
5 years, 6 months ago
Abbott India Limited is currently in a long term uptrend where the price is trading 11.8% above its 200 day moving average.
From a valuation standpoint, the stock is 60.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 7.7.
Abbott India Limited's total revenue rose by 1.6% to $11B since the same quarter in the previous year.
Its net income has dropped by 5.1% to $2B since the same quarter in the previous year.
Finally, its free cash flow fell by 6.0% to $3B since the same quarter in the previous year.
Based on the above factors, Abbott India Limited gets an overall score of 2/5.